RECRUITING

Biomechanical Precision Medicine Registry for Patients With and Without Heart Failure

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

In this single-center, longitudinal observational study, we will comprehensively examine clinical characteristics, proteomic, metabolomic, genomic and imaging data to better understand how different heart failure types may develop and progress over time. We will evaluate distinct sub-groups of heart failure (also known as heart failure phenotypes) and cardiomyopathies including amyloidosis with an ultimate goal of bringing the right medications and therapy to the right patients to optimize benefit and minimized side effects, an effort to improve precision medicine in heart failure.

Official Title

Preserved vs. Reduced Ejection Fraction Biomarker Registry and Precision Medicine Database for Ambulatory Heart Failure Patients (PREFER-HF) Study

Quick Facts

Study Start:2016-04-07
Study Completion:2027-10-06
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT03480633

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Abbie Macher, BS
CONTACT
617-643-6328
ajmacher@mgh.harvard.edu
Laura Stockhausen, BS
CONTACT
617-724-1339
lstockhausen@mgh.harvard.edu

Principal Investigator

Hanna Gaggin, MD, MPH
PRINCIPAL_INVESTIGATOR
Massachusetts General Hospital

Study Locations (Sites)

Massachusetts General Hospital
Boston, Massachusetts, 02114
United States

Collaborators and Investigators

Sponsor: Massachusetts General Hospital

  • Hanna Gaggin, MD, MPH, PRINCIPAL_INVESTIGATOR, Massachusetts General Hospital

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2016-04-07
Study Completion Date2027-10-06

Study Record Updates

Study Start Date2016-04-07
Study Completion Date2027-10-06

Terms related to this study

Keywords Provided by Researchers

  • Heart failure
  • Precision medicine
  • High risk patients
  • Pathophysiology
  • Bioregistry
  • Biomarkers
  • Heart failure etiology

Additional Relevant MeSH Terms

  • Heart Failure With Normal Ejection Fraction
  • Heart Failure With Reduced Ejection Fraction
  • Heart Failure, Right Sided
  • Heart Failure With Mid Range Ejection Fraction
  • Cardiovascular Risk Factor